The Oncotype DX® Breast Recurrence Score™
From the moment she is diagnosed, your patient counts on you to recommend the best treatment plan for her. You can count on the Oncotype DX Breast Recurrence Score.
|Only the Breast Recurrence Score
is validated for both prediction
of adjuvant therapy benefit and
The Breast Recurrence Score is a comprehensive 21-gene assay that provides a clearer picture of individual tumor biology, allowing you to make treatment decisions with increased confidence and insight.
Through its prediction of adjuvant therapy benefit as well as the likelihood of 10-year distant recurrence, the Breast Recurrence Score offers critical information not available from any other genomic test or traditional measure.
Studies show that use of the Breast Recurrence Score result changes treatment decisions approximately 30% of the time1 and addresses the clinical challenge of guiding therapy for those patients who will benefit from treatment while sparing other patients the rigors of unnecessary chemotherapy.
Only the Breast Recurrence Score
Next: Clinical Challenge